Presence of the C282Y Mutation (%) in Patients and Newborn Controls
| . | Group I . | . | Group II . | . |
|---|---|---|---|---|
| All patients | 17.1 (n = 117) | NS | 30.4 (n = 135) | P = .0005 (OR = 2.5) |
| cALL | 15.4 (n = 78) | NS | 36.3 (n = 102) | P = .00001 (OR = 3.2) |
| All males | 23.4 (n = 64) | P = .02 (OR = 2.2) | 34.7 (n = 75) | P = .0002 (OR = 3.0) |
| cALL (males) | 24.4 (n = 41) | P = .035 (OR = 2.3) | 45.5 (n = 55) | P < 5 × 10−6 (OR = 4.7) |
| All females | 9.4 (n = 53) | NS | 23.3 (n = 60) | NS |
| cALL (females) | 5.4 (n = 37) | NS | 25.5 (n = 47) | NS |
| CONTROLS | 12.3 (n = 415) | 15.1 (n = 238) |
| . | Group I . | . | Group II . | . |
|---|---|---|---|---|
| All patients | 17.1 (n = 117) | NS | 30.4 (n = 135) | P = .0005 (OR = 2.5) |
| cALL | 15.4 (n = 78) | NS | 36.3 (n = 102) | P = .00001 (OR = 3.2) |
| All males | 23.4 (n = 64) | P = .02 (OR = 2.2) | 34.7 (n = 75) | P = .0002 (OR = 3.0) |
| cALL (males) | 24.4 (n = 41) | P = .035 (OR = 2.3) | 45.5 (n = 55) | P < 5 × 10−6 (OR = 4.7) |
| All females | 9.4 (n = 53) | NS | 23.3 (n = 60) | NS |
| cALL (females) | 5.4 (n = 37) | NS | 25.5 (n = 47) | NS |
| CONTROLS | 12.3 (n = 415) | 15.1 (n = 238) |
Includes both homozygous and heterozygous occurrences of the mutation. There was 1 homozygous subject in each of the patient and control groups; NS, nonsignificant; OR, odds ratio; P values <.05 are shown for comparisons between the frequency in the leukemic group and the overall control group. In the control groups, there was no difference between gender-specific frequencies, but they were different in the patients with cALL both in group I (P = .03) and group II (P = .04). The overall frequencies were not different between the 2 control groups (P = .30).